Literature DB >> 12572843

Pathophysiology and assessment of neuropathic pain in Fabry disease.

R Schiffmann1, L J C Scott.   

Abstract

UNLABELLED: Severe neuropathic pain and hypohidrosis are important symptoms of Fabry disease, particularly in the first three decades of life. The pain is associated with a length-dependent small-fibre neuropathy that also causes a selective deficiency of cold perception. Cold exposure often accentuates the pain and worsens thermal perception. The hypohidrosis leads to poor exercise and heat tolerance. The mechanisms by which alpha-galactosidase A deficiency causes these physiological abnormalities are poorly understood. The stored glycolipid (globotriaosylceramide) may interfere with the function of cellular membrane proteins, such as ion channels, or may lead to cytotoxicity. The characteristic neuropathic pain can be symptomatically treated with various types of anticonvulsant drugs, such as carbamazepine. Improvement in neuropathic pain as a primary outcome measure has been useful in demonstrating that enzyme replacement therapy is effective in improving pain-related quality of life in Fabry disease.
CONCLUSIONS: The dysfunction of the peripheral nervous system is easily assessable and more readily reversible with specific therapy than the destructive processes that occur in organs such as the kidney. In future, therefore, it is likely that neuropathic pain, quantitative sensory testing and hypohidrosis will serve as clinical outcome measures for studies of specific and effective therapies for Fabry disease.

Entities:  

Mesh:

Year:  2002        PMID: 12572843     DOI: 10.1111/j.1651-2227.2002.tb03110.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  17 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

2.  Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Authors:  L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Journal:  J Inherit Metab Dis       Date:  2006-07-27       Impact factor: 4.982

3.  A survey of the pain experienced by males and females with Fabry disease.

Authors:  Andrea L Gibas; Regan Klatt; Jack Johnson; Joe T R Clarke; Joel Katz
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

4.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

5.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

6.  Social-adaptive and psychological functioning of patients affected by Fabry disease.

Authors:  Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta
Journal:  J Inherit Metab Dis       Date:  2010-01-20       Impact factor: 4.982

7.  Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.

Authors:  Kevin Mills; Ashok Vellodi; Peter Morris; Donald Cooper; Michael Morris; Elisabeth Young; Bryan Winchester
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

8.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

9.  Painful peripheral neuropathies.

Authors:  P Marchettini; M Lacerenza; E Mauri; C Marangoni
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 10.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.